U.S. flag

An official website of the United States government

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Links from Books

Items: 20

1.
Avelumab in patients with previously treated metastatic Merkel cell carcinoma (JAVELIN Merkel 200): updated overall survival data after >5 years of follow-up
S.P. D'Angelo, S. Bhatia, A.S. Brohl, O. Hamid, J.M. Mehnert, P. Terheyden, K.C. Shih, I. Brownell, C. Lebbé, K.D. Lewis, G.P. Linette, M. Milella, H. Xiong, G. Guezel, P.T. Nghiem
ESMO Open. 2021 Dec; 6(6): 100290. Published online 2021 Oct 26. doi: 10.1016/j.esmoop.2021.100290
PMCID:
PMC8564559
AbstractArticlePDF–351K
2.
Efficacy and immune-related adverse event associations in avelumab-treated patients
Karen Kelly, Juliane Manitz, Manish R Patel, Sandra P D’Angelo, Andrea B Apolo, Arun Rajan, Vijay Kasturi, Isabell Speit, Marcis Bajars, John Warth, James L Gulley
J Immunother Cancer. 2020; 8(2): e001427. Published online 2020 Nov 20. doi: 10.1136/jitc-2020-001427
PMCID:
PMC7682456
AbstractArticlePDF–1.1M
3.
Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial
Anthony B El-Khoueiry, Bruno Sangro, Thomas Yau, Todd S Crocenzi, Masatoshi Kudo, Chiun Hsu, Tae-You Kim, Su-Pin Choo, Jörg Trojan, Theodore H Welling, 3rd, Tim Meyer, Yoon-Koo Kang, Winnie Yeo, Akhil Chopra, Jeffrey Anderson, Christine dela Cruz, Lixin Lang, Jaclyn Neely, Hao Tang, Homa B Dastani, Ignacio Melero
Lancet. Author manuscript; available in PMC 2020 Oct 7.
Published in final edited form as: Lancet. 2017 Jun 24; 389(10088): 2492–2502. Published online 2017 Apr 20. doi: 10.1016/S0140-6736(17)31046-2
PMCID:
PMC7539326
AbstractArticlePDF–1.0M
4.
Immune Checkpoint Inhibitors and Immune-Related Adverse Drug Reactions: Data From Italian Pharmacovigilance Database
Rosanna Ruggiero, Federica Fraenza, Cristina Scavone, Gabriella di Mauro, Raffaele Piscitelli, Annamaria Mascolo, Carmen Ferrajolo, Concetta Rafaniello, Liberata Sportiello, Francesco Rossi, Annalisa Capuano
Front Pharmacol. 2020; 11: 830. Published online 2020 Jun 9. doi: 10.3389/fphar.2020.00830
PMCID:
PMC7295943
AbstractArticlePDF–1.0M
5.
Avelumab in patients with previously treated metastatic Merkel cell carcinoma: long-term data and biomarker analyses from the single-arm phase 2 JAVELIN Merkel 200 trial
Sandra P D'Angelo, Shailender Bhatia, Andrew S Brohl, Omid Hamid, Janice M Mehnert, Patrick Terheyden, Kent C Shih, Isaac Brownell, Celeste Lebbé, Karl D Lewis, Gerald P Linette, Michele Milella, Sara Georges, Parantu Shah, Barbara Ellers-Lenz, Marcis Bajars, Gülseren Güzel, Paul T Nghiem
J Immunother Cancer. 2020; 8(1): e000674. Published online 2020 May 15. doi: 10.1136/jitc-2020-000674
PMCID:
PMC7239697
AbstractArticlePDF–1.6M
6.
Safety and efficacy of immune checkpoint inhibitors in patients with HBV/HCV infection and advanced-stage cancer: A systematic review
Dan Pu, Liyuan Yin, Yuwen Zhou, Wen Li, Lin Huang, Liang Cai, Qinghua Zhou
Medicine (Baltimore) 2020 Jan; 99(5): e19013. Published online 2020 Jan 31. doi: 10.1097/MD.0000000000019013
PMCID:
PMC7004734
AbstractArticlePDF–204K
7.
Programmed cell death-1 inhibitor-related sclerosing cholangitis: A systematic review
Takumi Onoyama, Yohei Takeda, Taro Yamashita, Wataru Hamamoto, Yuri Sakamoto, Hiroki Koda, Soichiro Kawata, Kazuya Matsumoto, Hajime Isomoto
World J Gastroenterol. 2020 Jan 21; 26(3): 353–365. Published online 2020 Jan 21. doi: 10.3748/wjg.v26.i3.353
PMCID:
PMC6969883
AbstractArticlePDF–3.4M
8.
Efficacy and tolerability of anti-programmed death-ligand 1 (PD-L1) antibody (Avelumab) treatment in advanced thymoma
Arun Rajan, Christopher R. Heery, Anish Thomas, Andrew L. Mammen, Susan Perry, Geraldine O’Sullivan Coyne, Udayan Guha, Arlene Berman, Eva Szabo, Ravi A. Madan, Leomar Y. Ballester, Stefania Pittaluga, Renee N. Donahue, Yo-Ting Tsai, Lauren M. Lepone, Kevin Chin, Fiona Ginty, Anup Sood, Stephen M. Hewitt, Jeffrey Schlom, Raffit Hassan, James L. Gulley
J Immunother Cancer. 2019; 7: 269. Published online 2019 Oct 21. doi: 10.1186/s40425-019-0723-9
PMCID:
PMC6805423
AbstractArticlePDF–1.4M
9.
Case series of cancer patients who developed cholecystitis related to immune checkpoint inhibitor treatment
Hamzah Abu-Sbeih, Cynthia Nguyen Tran, Phillip S. Ge, Manoop S. Bhutani, Mazen Alasadi, Aung Naing, Amir A. Jazaeri, Yinghong Wang
J Immunother Cancer. 2019; 7: 118. Published online 2019 May 3. doi: 10.1186/s40425-019-0604-2
PMCID:
PMC6499962
AbstractArticlePDF–717K
10.
Avelumab for metastatic or locally advanced previously treated solid tumours (JAVELIN Solid Tumor): a phase 1a, multicohort, dose-escalation trial
Christopher R Heery, Geraldine O’Sullivan-Coyne, Ravi A Madan, Lisa Cordes, Arun Rajan, Myrna Rauckhorst, Elizabeth Lamping, Israel Oyelakin, Jennifer L Marté, Lauren M Lepone, Renee N Donahue, Italia Grenga, Jean-Marie Cuillerot, Berend Neuteboom, Anja von Heydebreck, Kevin Chin, Jeffrey Schlom, James L Gulley
Lancet Oncol. Author manuscript; available in PMC 2019 Feb 24.
Published in final edited form as: Lancet Oncol. 2017 May; 18(5): 587–598. Published online 2017 Mar 31. doi: 10.1016/S1470-2045(17)30239-5
PMCID:
PMC6387686
AbstractArticlePDF–985K
11.
Phase III, randomised trial of avelumab versus physician’s choice of chemotherapy as third-line treatment of patients with advanced gastric or gastro-oesophageal junction cancer: primary analysis of JAVELIN Gastric 300
Y -J Bang, E Yañez Ruiz, E Van Cutsem, K -W Lee, L Wyrwicz, M Schenker, M Alsina, M -H Ryu, H -C Chung, L Evesque, S -E Al-Batran, S H Park, M Lichinitser, N Boku, M H Moehler, J Hong, H Xiong, R Hallwachs, I Conti, J Taieb
Ann Oncol. 2018 Oct; 29(10): 2052–2060. Published online 2018 Jul 24. doi: 10.1093/annonc/mdy264
PMCID:
PMC6225815
AbstractArticlePDF–244K
12.
Avelumab in patients with chemotherapy-refractory metastatic Merkel cell carcinoma: a multicentre, single-group, open-label, phase 2 trial
Prof. Howard L Kaufman, Jeffery Russell, Omid Hamid, Shailender Bhatia, Patrick Terheyden, Sandra P D’Angelo, Kent C Shih, Prof. Céleste Lebbé, Gerald P Linette, Michele Milella, Isaac Brownell, Karl D Lewis, Jochen H Lorch, Kevin Chin, Lisa Mahnke, Anja von Heydebreck, Jean-Marie Cuillerot, Prof. Paul Nghiem
Lancet Oncol. Author manuscript; available in PMC 2017 Sep 6.
Published in final edited form as: Lancet Oncol. 2016 Oct; 17(10): 1374–1385. Published online 2016 Sep 1. doi: 10.1016/S1470-2045(16)30364-3
PMCID:
PMC5587154
AbstractArticlePDF–848K
13.
Avelumab for patients with previously treated metastatic or recurrent non-small-cell lung cancer (JAVELIN Solid Tumor): dose-expansion cohort of a multicentre, open-label, phase 1b trial
James L. Gulley, Arun Rajan, David R. Spigel, Nicholas Iannotti, Jason Chandler, Deborah J. L. Wong, Joseph Leach, W. Jeff Edenfield, Ding Wang, Hans Juergen Grote, Anja von Heydebreck, Kevin Chin, Jean-Marie Cuillerot, Karen Kelly
Lancet Oncol. Author manuscript; available in PMC 2018 May 1.
Published in final edited form as: Lancet Oncol. 2017 May; 18(5): 599–610. Published online 2017 Mar 31. doi: 10.1016/S1470-2045(17)30240-1
PMCID:
PMC5522719
AbstractArticlePDF–763K
14.
Avelumab, an Anti–Programmed Death-Ligand 1 Antibody, In Patients With Refractory Metastatic Urothelial Carcinoma: Results From a Multicenter, Phase Ib Study
Andrea B. Apolo, Jeffrey R. Infante, Ani Balmanoukian, Manish R. Patel, Ding Wang, Karen Kelly, Anthony E. Mega, Carolyn D. Britten, Alain Ravaud, Alain C. Mita, Howard Safran, Thomas E. Stinchcombe, Marko Srdanov, Arnold B. Gelb, Michael Schlichting, Kevin Chin, James L. Gulley
J Clin Oncol. 2017 Jul 1; 35(19): 2117–2124. Published online 2017 Apr 4. doi: 10.1200/JCO.2016.71.6795
PMCID:
PMC5493051
AbstractArticlePDF–849K
15.
PD-1 Blockade in Advanced Melanoma in Patients with Hepatitis C and/or HIV
Diwakar Davar, Melissa Wilson, Chelsea Pruckner, John M. Kirkwood
Case Rep Oncol Med. 2015; 2015: 737389. Published online 2015 Sep 10. doi: 10.1155/2015/737389
PMCID:
PMC4581502
AbstractArticlePDF–1015K
16.
PD-1 blockade induces responses by inhibiting adaptive immune resistance
Paul C. Tumeh, Christina L. Harview, Jennifer H. Yearley, I. Peter Shintaku, Emma J. M. Taylor, Lidia Robert, Bartosz Chmielowski, Marko Spasic, Gina Henry, Voicu Ciobanu, Alisha N. West, Manuel Carmona, Christine Kivork, Elizabeth Seja, Grace Cherry, Antonio Gutierrez, Tristan R. Grogan, Christine Mateus, Gorana Tomasic, John A. Glaspy, Ryan O. Emerson, Harlan Robins, Robert H. Pierce, David A. Elashoff, Caroline Robert, Antoni Ribas
Nature. Author manuscript; available in PMC 2015 May 26.
Published in final edited form as: Nature. 2014 Nov 27; 515(7528): 568–571. doi: 10.1038/nature13954
PMCID:
PMC4246418
AbstractArticlePDF–4.2M
17.
Pathologic Changes in Ipilimumab-related Hepatitis in Patients with Metastatic Melanoma
David E. Kleiner, David Berman
Dig Dis Sci. Author manuscript; available in PMC 2013 Oct 8.
Published in final edited form as: Dig Dis Sci. 2012 Aug; 57(8): 2233–2240. Published online 2012 Mar 21. doi: 10.1007/s10620-012-2140-5
PMCID:
PMC3792485
AbstractArticlePDF–2.4M
18.
Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer
Julie R. Brahmer, Scott S. Tykodi, Laura Q.M. Chow, Wen-Jen Hwu, Suzanne L. Topalian, Patrick Hwu, Charles G. Drake, Luis H. Camacho, John Kauh, Kunle Odunsi, Henry C. Pitot, Omid Hamid, Shailender Bhatia, Renato Martins, Keith Eaton, Shuming Chen, Theresa M. Salay, Suresh Alaparthy, Joseph F. Grosso, Alan J. Korman, Susan M. Parker, Shruti Agrawal, Stacie M. Goldberg, Drew M. Pardoll, Ashok Gupta, Jon M. Wigginton
N Engl J Med. Author manuscript; available in PMC 2013 Feb 4.
Published in final edited form as: N Engl J Med. 2012 Jun 28; 366(26): 2455–2465. Published online 2012 Jun 2. doi: 10.1056/NEJMoa1200694
PMCID:
PMC3563263
AbstractArticlePDF–1.5M
19.
Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer
Suzanne L. Topalian, F. Stephen Hodi, Julie R. Brahmer, Scott N. Gettinger, David C. Smith, David F. McDermott, John D. Powderly, Richard D. Carvajal, Jeffrey A. Sosman, Michael B. Atkins, Philip D. Leming, David R. Spigel, Scott J. Antonia, Leora Horn, Charles G. Drake, Drew M. Pardoll, Lieping Chen, William H. Sharfman, Robert A. Anders, Janis M. Taube, Tracee L. McMiller, Haiying Xu, Alan J. Korman, Maria Jure-Kunkel, Shruti Agrawal, Daniel McDonald, Georgia D. Kollia, Ashok Gupta, Jon M. Wigginton, Mario Sznol
N Engl J Med. Author manuscript; available in PMC 2013 Jan 14.
Published in final edited form as: N Engl J Med. 2012 Jun 28; 366(26): 2443–2454. Published online 2012 Jun 2. doi: 10.1056/NEJMoa1200690
PMCID:
PMC3544539
AbstractArticlePDF–1.5M
20.
Cancer regression and autoimmunity induced by cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma
Giao Q. Phan, James C. Yang, Richard M. Sherry, Patrick Hwu, Suzanne L. Topalian, Douglas J. Schwartzentruber, Nicholas P. Restifo, Leah R. Haworth, Claudia A. Seipp, Linda J. Freezer, Kathleen E. Morton, Sharon A. Mavroukakis, Paul H. Duray, Seth M. Steinberg, James P. Allison, Thomas A. Davis, Steven A. Rosenberg
Proc Natl Acad Sci U S A. 2003 Jul 8; 100(14): 8372–8377. Published online 2003 Jun 25. doi: 10.1073/pnas.1533209100
PMCID:
PMC166236
AbstractArticlePDF–644K

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Filter your results:

Find related data

Recent activity

Clear Turn Off Turn On

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...
You are here: NCBI > Literature > PubMed Central (PMC)
Support Center